Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Pharvaris N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ZUG, SWITZERLAND, JULY 22, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE PUBLICATION OF A COMPREHENSIVE REVIEW ARTICLE IN CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY PROVIDING A STATE-OF-THE-ART OVERVIEW OF THE BIOLOGY OF BRADYKININ AND THE BRADYKININ B2 RECEPTOR (B2R), AND SUMMARIZING THE GROWING BODY OF EVIDENCE SUPPORTING B2R ANTAGONISM AS A THERAPEUTIC STRATEGY FOR BRADYKININ-MEDIATED DISEASES. DRAWING ON DECADES OF SCIENTIFIC AND CLINICAL RESEARCH, THE ARTICLE TRACES THE EVOLUTION OF BRADYKININ B2 RECEPTOR ANTAGONISM FROM FOUNDATIONAL DISCOVERIES IN KININ BIOLOGY TO A CLINICALLY VALIDATED THERAPEUTIC APPROACH.

PUBLICATION IN CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY SUMMARIZES DECADES OF EVIDENCE SUPPORTING BRADYKININ B2 RECEPTOR AS A VALIDATED THERAPEUTIC TARGET IN BRADYKININ-MEDIATED ANGIOEDEMA

ZUG, SWITZERLAND, JULY 06, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED ITS NEW DRUG APPLICATION (NDA) FOR DEUCRICTIBANT IMMEDIATE-RELEASE (IR) CAPSULE (20 MG) FOR THE ON-DEMAND TREATMENT (ODT) OF HEREDITARY ANGIOEDEMA (HAE) ATTACKS. THE FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF APRIL 23, 2027.

PHARVARIS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR DEUCRICTIBANT IR FOR ON-DEMAND TREATMENT OF HEREDITARY ANGIOEDEMA ATTACKS

ZUG, SWITZERLAND, JUNE 15, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED ANGIOEDEMA, SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), SUMMARIZED THE PRESENTATIONS FROM THE EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY (EAACI) ANNUAL CONGRESS 2026, WHICH TOOK PLACE FROM JUNE 12-15, 2026, IN ISTANBUL, TURKEY.

DATA SUPPORTING DIFFERENTIATED PROFILE OF DEUCRICTIBANT IN HAE MANAGEMENT PRESENTED AT EAACI 2026

ZUG, SWITZERLAND, JUNE 11, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE ANNUAL GENERAL MEETING OF SHAREHOLDERS WILL TAKE PLACE ON FRIDAY, JUNE 26, 2026, AT 16:00 CEST (10:00 A.M. EDT).

PHARVARIS ANNOUNCES ANNUAL GENERAL MEETING OF SHAREHOLDERS

ZUG, SWITZERLAND, MAY 29, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE ACCEPTANCE OF ONE ABSTRACT FOR ORAL PRESENTATION AND SEVEN ABSTRACTS FOR FLASH TALK/POSTER PRESENTATION AT THE EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY (EAACI) ANNUAL CONGRESS 2026, TO BE HELD FROM JUNE 12-15, 2026, IN ISTANBUL, TURKEY.

PHARVARIS TO PRESENT CLINICAL DATA AT THE EAACI ANNUAL CONGRESS 2026

TOPLINE DATA FROM CHAPTER-3, A PIVOTAL PHASE 3 STUDY OF DEUCRICTIBANT XR FOR THE PROPHYLAXIS OF HAE ATTACKS, EXPECTED IN 3Q2026 TIMELINE FOR SUBMISSION OF NDA OF DEUCRICTIBANT IR FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS REMAINS ON-TRACK IN 1H2026 ENROLLMENT ONGOING IN CREAATE, A PIVOTAL STUDY OF DEUCRICTIBANT FOR THE PROPHYLACTIC AND ON-DEMAND TREATMENT OF AAE-C1INH ATTACKS CASH AND CASH EQUIVALENTS OF 247 MILLION AS OF MARCH 31, 2026; SUBSEQUENT CLOSING OF $132 MILLION UNDERWRITTEN OFFERING EXTENDS CASH RUNWAY INTO 2028 ZUG, SWITZERLAND, MAY 12, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED IN MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE. IN 2026, PHARVARIS REMAINS FOCUSED ON EXECUTION ACROSS OUR LATE-STAGE PROGRAMS, INCLUDING REPORTING CHAPTER-3 DATA IN THE THIRD QUARTER AND ENROLLING IN CREAATE, AND ON ESTABLISHING OUR COMMERCIAL INFRASTRUCTURE IN PREPARATION FOR THE POTENTIAL LAUNCH OF DEUCRICTIBANT IR, SAID BERNDT MODIG, CHIEF EXECUTIVE OFFICER OF PHARVARIS.

PHARVARIS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ZUG, SWITZERLAND, MAY 11, 2026 (GLOBE NEWSWIRE) -- PHARVARIS N.V. (PHARVARIS, NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN OFFERING OF 4,455,863 ORDINARY SHARES (WHICH INCLUDES THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE UP TO AN ADDITIONAL 581,199 ORDINARY SHARES). THE GROSS PROCEEDS TO PHARVARIS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS, COMMISSIONS AND OTHER OFFERING EXPENSES, WERE APPROXIMATELY $132.3 MILLION. ALL SHARES IN THE OFFERING WERE SOLD BY PHARVARIS.

PHARVARIS ANNOUNCES CLOSING OF $132.3 MILLION UNDERWRITTEN OFFERING OF ORDINARY SHARES AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

ZUG, SWITZERLAND, MAY 08, 2026 (GLOBE NEWSWIRE) -- PHARVARIS N.V. (PHARVARIS, NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), ANNOUNCED TODAY THE PRICING OF AN UNDERWRITTEN OFFERING OF 3,874,664 OF ITS ORDINARY SHARES AT A PRICE OF $29.68 PER SHARE. ALL SHARES IN THE OFFERING ARE TO BE SOLD BY PHARVARIS. IN ADDITION, PHARVARIS HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 581,199 ORDINARY SHARES AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE GROSS PROCEEDS TO PHARVARIS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $115 MILLION, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT MAY 11, 2026, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

PHARVARIS ANNOUNCES PRICING OF $115 MILLION UNDERWRITTEN OFFERING OF ORDINARY SHARES

ZUG, SWITZERLAND, APRIL 20, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), PRESENTED DATA EVALUATING SAFETY MARGINS OF ADMINISTRATION OF DEUCRICTIBANT IMMEDIATE-RELEASE (IR) CAPSULE(S) IN COMBINATION WITH DEUCRICTIBANT EXTENDED-RELEASE (XR) TABLET AT THE CONSORTIUM OF INDEPENDENT IMMUNOLOGY CLINICS (CIIC) SPRING 2026 CONFERENCE, WHICH TOOK PLACE FROM APRIL 17-19, 2026, IN ARLINGTON, TX.

EVIDENCE SUPPORTING COMBINED USE OF DEUCRICTIBANT IR WITH DEUCRICTIBANT XR PRESENTED AT CIIC SPRING 2026 CONFERENCE

ZUG, SWITZERLAND, APRIL 02, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A BUSINESS UPDATE.

Pharvaris N.V.

PHVS

Price

Financial Reports

No items found.

Press Releases

Pharvaris N.V.

PHVS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PHVS